Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177362 | 0.94 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDHSD17B10POLL | |
| SCHEMBL349470 | 0.79 | ALDH1A1 (0.32) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL351988 | 0.78 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDHSD17B10POLL | |
| SCHEMBL10177361 | 0.78 | POLL (0.39) | KDM4EALDH1A1HPGDHSD17B10POLL | |
| SCHEMBL350523 | 0.78 | CA1 (0.39) | KDM4EALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL10177383 | 0.73 | ALDH1A1 (0.31) | ALDH1A1HTTKMT2A | |
| SCHEMBL30865720 | 0.72 | CA1 (0.44) | KDM4EALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL10177358 | 0.67 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL18922475 | 0.66 | ACHE (0.45) | KDM4EALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL351987 | 0.65 | CA1 (0.42) | KDM4EALDH1A1HPGDHSD17B10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593226-B1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-11-14 | — | — | EP | claimed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| US-9381508-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-12-17 | — | — | US | claimed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | claimed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | claimed |
| US-8975443-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-03-10 | — | — | US | claimed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | claimed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | claimed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | claimed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| EP-2593226-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012009698-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | claimed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | claimed |
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009698-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | KDM4E 3762/4885ALDH1A1 4611/4885HPGD 1936/4885 |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | KDM4E 3762/4885ALDH1A1 4611/4885HPGD 1936/4885 |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | KDM4E 3762/4885ALDH1A1 4611/4885HPGD 1936/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | KDM4E 3572/4885ALDH1A1 2059/4885HPGD 3124/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | KDM4E 3814/4885ALDH1A1 4364/4885HPGD 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.